Table 1 Anti-leukemia activities of KPT-8602 and selinexor in vitro
AML cell lines | KPT-8602—IC 50 (n M ) at 72h | Selinexor—IC 50 (n M ) at 72h | Ratio |
|---|---|---|---|
OCI-AML2 | 19 | 40 | 0.48 |
MV411 | 30 | 50 | 0.61 |
MOLM13 | 32 | 47 | 0.68 |
KG1 | 66 | 151 | 0.44 |
SKM1 | 84 | 120 | 0.70 |
Kasumi-1 | 113 | 172 | 0.65 |
OCI-AML3 | 127 | 154 | 0.82 |
Mono-MacI | 167 | 179 | 0.93 |
U937 | 205 | 327 | 0.62 |
NB4 | 211 | 304 | 0.69 |
